Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Clinical trial NCT06607757 · RECRUITING

Trial details

NCT number: NCT06607757
Sponsor: GBG Forschungs GmbH
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Start date: 2024-12-04
Primary completion: 2026-06-30
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.